ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
about
Analysis of folylpoly-gamma-glutamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cellsDesign, Synthesis, and X-ray Crystal Structure of Classical and Nonclassical 2-Amino-4-oxo-5-substituted-6-ethylthieno[2,3- d ]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors and as Potential Antitumor AgentsDesign, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitorsInhibitor-bound complexes of dihydrofolate reductase-thymidylate synthase from Babesia bovisDevelopment and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targetsAntisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cellsMurine cytomegalovirus stimulates cellular thymidylate synthase gene expression in quiescent cells and requires the enzyme for replicationAntisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cellsAn innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymesTrypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate SynthaseA phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administrationSchedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.Role of RecA and the SOS response in thymineless death in Escherichia coli.One-carbon metabolism and nucleotide biosynthesis as attractive targets for anticancer therapy.2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase.Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum.The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.The role of DNA synthesis imaging in cancer in the era of targeted therapeuticsKinetics of Plasmodium falciparum thymidylate synthase: interactions with high-affinity metabolites of 5-fluoroorotate and D1694Population pharmacokinetics of raltitrexed in patients with advanced solid tumoursAltered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancerBiweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II studyInvolvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex.Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1)Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase.The antifolatesSynthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate tThe effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
P2860
Q21260431-F762930B-F6ED-4F04-BD56-D4FA46D2A180Q27657240-CD8A03FD-FD5D-4CAF-AA04-2938EE8EAB65Q27667755-BEE51ADB-B8BF-4DAF-B533-114DB51BFD03Q27673544-689EC78A-EA40-46F7-9DD8-DC1ECB6BC93DQ27678339-83F5C34C-AEAF-43D3-8ACB-EF8C48F0603DQ28343570-FCC3E597-846D-4171-A0D0-9025237B67D9Q28344246-BD45DEED-C0CC-4C8F-9DBB-8B9F376FD9F0Q28365365-E8EA4E43-819A-4B4F-97CA-63C373A09F57Q28486030-B0A3CC26-A3D7-46C0-AD54-38D202C89ED4Q28552051-1E4E85AD-A15F-495F-A82D-11659A5A60F3Q30321809-EF7429ED-90BE-4DF9-960B-E246DC2BB785Q31927270-518FA4CD-3BF5-474A-BAE9-7911E053D8FEQ33539733-4C26DF42-60D8-4771-BDCC-F42D30188116Q33618935-8F9D8A8B-82B2-472E-A25E-C203E5300B97Q33639893-F926F227-9AC8-4570-B3A0-31D2912C074CQ33750695-72A2B02D-3467-4F73-80F5-C4DE7244BB97Q33979229-CD8D19AE-C9ED-4479-AD8B-821AEA7E4F24Q34297931-F9E23A84-E728-4DC1-BCA0-78717F6D304BQ34907192-5D6661C3-1C6B-4EA8-AC56-A7AD334B987AQ35125528-9E834314-FB31-4B90-B2A3-2D91F57C42C9Q35826027-69572A9B-209D-4725-9FC5-2D75CCB238F6Q36024905-2225466F-D824-4F02-B838-EE2D627FAF25Q36080853-7BFCCCE9-4538-4604-BA97-971B7B2053D5Q36080916-8964B3C6-0706-4840-AE8E-83EAF3CD6048Q36115065-5F66F380-EFB5-4199-BBEE-0DE5E62A98E3Q36115728-25A938C4-D285-49C2-95AF-22DA44927D13Q36116454-78B7C0AE-FA04-434E-B242-A307CEBE4BA8Q36291281-37980D4E-7E59-4DF2-AD6C-D9D9E2E274ADQ36294938-47C4F2DF-88FB-4525-8224-F330B88EAF05Q36372894-9BE3234B-0396-4C16-B23F-2138B6DDE7ADQ36422780-14E4859F-A96F-4C3C-BA00-088468F0FD48Q36614369-B633DD37-FC64-447D-B2A2-69B1E0D7192CQ36619564-D6D5E0DC-6E1A-4A19-8240-5F684022B4B8Q36621705-2A07DEAD-DAA3-49A3-99EC-1D3B310CFA6FQ36641384-BA49FC9E-DF98-4F74-805C-6142D161EE31Q36899323-213F29A5-B88B-41C6-8B3F-EB4771425463Q36981985-864BA1DF-D938-443F-8BCF-A2282FD5324EQ37183495-7AA6CE09-B2FD-4678-B3DC-264DD0CA8E5AQ37313482-66545746-B517-4533-8CA1-62A9164DE4EFQ37380738-7BD0D72C-542D-4929-B202-F83058EF72C8
P2860
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
ICI D1694, a quinazoline antif ...... new agent for clinical study.
@en
type
label
ICI D1694, a quinazoline antif ...... new agent for clinical study.
@en
prefLabel
ICI D1694, a quinazoline antif ...... new agent for clinical study.
@en
P2093
P1433
P1476
ICI D1694, a quinazoline antif ...... new agent for clinical study.
@en
P2093
Calvert AH
Jackman AL
P304
P407
P577
1991-10-01T00:00:00Z